American Century Companies Inc. Makes New Investment in AtriCure, Inc. (NASDAQ:ATRC)

American Century Companies Inc. acquired a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,872 shares of the medical device company's stock, valued at approximately $516,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ATRC. Captrust Financial Advisors bought a new position in shares of AtriCure in the third quarter valued at $230,000. State Street Corp grew its position in AtriCure by 4.9% during the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after buying an additional 63,002 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in AtriCure in the third quarter worth about $614,000. Geode Capital Management LLC grew its position in shares of AtriCure by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock valued at $32,326,000 after acquiring an additional 32,676 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of AtriCure by 0.9% during the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock worth $1,569,000 after purchasing an additional 484 shares during the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Trading Down 0.8 %

NASDAQ:ATRC traded down $0.25 during mid-day trading on Thursday, reaching $31.84. 44,389 shares of the company's stock traded hands, compared to its average volume of 578,738. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -33.51 and a beta of 1.65. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The company has a 50 day moving average price of $35.49 and a 200-day moving average price of $34.31. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62.

Insider Buying and Selling

In other news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ATRC has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their price objective on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, March 27th. Oppenheimer lifted their price objective on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. Piper Sandler lifted their price target on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $51.00 target price on shares of AtriCure in a research note on Thursday, March 27th. Finally, BTIG Research reissued a "buy" rating on shares of AtriCure in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $49.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.